Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 10;73(2):175–182. doi: 10.1093/cid/ciaa961

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 3. — The mean change of therapeutic effect factors at different time points following GLS4 and ritonavir combination or entecavir treatment. Patients in cohort A were treated with a combination of GLS4 120 mg/day and ritonavir 100 mg/day; cohort B, GLS4 240 mg/day and ritonavir 100 mg/day; and cohort C, entecavir 0.5 mg/day for 28 days. A–F show the means changes in mean HBV DNA, HBsAg, HBeAg, HBcrAg, HBV pgRNA, and ALT values, respectively. Abbreviations: ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBcrAg, hepatitis B core-related antigen; HBV, hepatitis B virus; pgRNA, pregenomic RNA.